AEGiS-FDA: New 300 mg Reyataz capsule approved Food and Drug AdministrationImportant note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow


New 300 mg Reyataz capsule approved

Food and Drug Administration - October 23, 2006


On October 16, 2006, the Food and Drug Administration approved a new 300 mg capsule form of Reyataz (atazanavir).

Reyataz is now available as 100mg, 150 mg, 200 mg, and the new 300 mg capsules.

The new 300 mg capsules give treatment-experienced patients the option to take either one 300 mg capsule, or two 150 mg capsules of Reyataz, once daily plus ritonavir 100 mg once daily, with food.

The recommended dose for treatment-na ve patients remains unchanged and is Reyataz 400 mg (two 200mg capsules) once daily with food.

Reyataz is a product of Bristol-Myers Squibb.

Richard Klein | Office of Special Health Issues | Food and Drug Administration

Kimberly Struble | Division of Antiviral Drug Products | Food and Drug Administration
061023
FD061004


SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .